4D Molecular Therapeutics (FDMT) Other Non-Current Liabilities (2019 - 2025)
Historic Other Non-Current Liabilities for 4D Molecular Therapeutics (FDMT) over the last 7 years, with Q3 2025 value amounting to $345000.0.
- 4D Molecular Therapeutics' Other Non-Current Liabilities fell 1287.88% to $345000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $345000.0, marking a year-over-year decrease of 1287.88%. This contributed to the annual value of $410000.0 for FY2024, which is 1111.11% up from last year.
- Per 4D Molecular Therapeutics' latest filing, its Other Non-Current Liabilities stood at $345000.0 for Q3 2025, which was down 1287.88% from $334000.0 recorded in Q2 2025.
- Over the past 5 years, 4D Molecular Therapeutics' Other Non-Current Liabilities peaked at $1.9 million during Q3 2021, and registered a low of $212000.0 during Q4 2022.
- In the last 5 years, 4D Molecular Therapeutics' Other Non-Current Liabilities had a median value of $345000.0 in 2025 and averaged $548842.1.
- Per our database at Business Quant, 4D Molecular Therapeutics' Other Non-Current Liabilities plummeted by 8871.22% in 2022 and then surged by 8018.87% in 2024.
- Quarter analysis of 5 years shows 4D Molecular Therapeutics' Other Non-Current Liabilities stood at $214000.0 in 2021, then decreased by 0.93% to $212000.0 in 2022, then soared by 74.06% to $369000.0 in 2023, then increased by 11.11% to $410000.0 in 2024, then dropped by 15.85% to $345000.0 in 2025.
- Its last three reported values are $345000.0 in Q3 2025, $334000.0 for Q2 2025, and $322000.0 during Q1 2025.